Adeno-associated virus (AAV) is a promising vector for human somatic gene therapy. However, its broad host range is a disadvantage for in vivo gene therapy, because it does not allow the selective ...

Pacira BioSciences Inc. (NASDAQ:PCRX) is one of the most undervalued small-cap stocks to buy according to analysts. On June ...

We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a ...

Identification of the AAV receptor and vector-specific reagents has led to the development of purification protocols for rAAV vectors by affinity (receptor/antibody) matrix chromatography.

They present a novel adenoviral vector that binds to the EphA2 receptor (EphA2R). This receptor is highly expressed in several solid tumors including pancreatic cancer.

Denali targets the transferrin receptor to deliver a TREM2 antibody, the progranulin protein, and iduronate-2-sulfatase, an enzyme defective in Hunter syndrome, into the brain (Jan 2023 news; Apr 2023 ...

Effective analgesics have been in use for thousands of years, yet our ability to use them to treat localized pain is limited by interaction of the drug with other than the desired receptors. High ...

Bladder cancers (BCs) that invade the muscle layer are classified as muscle-invasive bladder cancers (MIBCs). The MIBC subtype accounts for around 25% of all BC cases, with a significant proportion of ...

Biotech entrepreneur George Church launches gene therapy startup to design safer viral vectors By Angus Liu Feb 10, 2021 2:00pm academic research Cell & Gene Therapy gene therapy Toll-like receptors ...

Graphic illustration of DRG-101 (DeltaRex-G). This Chimeric Antigen Receptor Vector (CAR-V) displays a Sig targeting peptide on its gp70 env (A), for binding to Signature (Sig) Proteins in the ...

Easy accessibility and effectiveness of catnip could be important in developing countries where mosquito-borne diseases are a huge problem.

Chimeric antigen receptor–modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whether chimeric ...